Both, COX1 and COX2 overexpression have been strongly implicated in the progression of numerous tumors, including ovarian cancer [45], but the clinical utility of available COX2 inhibitors is limited due to their cardiotoxicity. This evidence concerns the gene PTGS1 and ovarian carcinoma.